ArmaGen’s proprietary platform technology fuses a therapeutic to an antibody that binds to the specific receptors that deliver insulin, transferrin, or LRP1 (or any future receptor not yet identified) tothe brain, enabling the fusion protein to travel through the BBB in a process known as receptor-mediated transcytosis. ArmaGen’s platform is unique as it targets multiple antibody-based receptor-mediated transporters.

ArmaGen: Transporting Therapies Across the Blood‑Brain Barrier

ArmaGen Technology Platform
ArmaGen’s platform can non-invasively transport a range of therapies – including recombinant proteins, monoclonal antibodies (mAbs) and short inhibitory RNA (siRNA) – to targets in the brain. ArmaGen scientists achieved this by genetically engineering a novel fusion protein, and fusing the therapeutic of interest to a mAb fragment. The mAb fragment then binds to a receptor (e.g., human insulin receptor [HIR], transferrin receptor, low-density lipoprotein receptor-related protein 1 [LRP1] receptor) that is already present on the blood-brain barrier (BBB), triggering transcytosis or transport across the BBB.

Following transcytosis, the therapeutic may act in several different ways:

  1. Binding with soluble ligands (molecules that bind to receptors) such as inflammatory proteins
  2. Transmitting a secondary message through binding to an additional receptor (such as glial cell-derived neurotrophic factor [GDNF] or erythropoietin [EPO]) on the surface of the cell membrane
  3. Binding to insulin receptors on the surface of the cell membrane to deliver its payload within the neuron, as a means to treat lysosomal storage diseases such as Hunter and Hurler syndromes
  4. Preventing expression of a gene through delivery of therapeutics such as siRNA into the nucleus of the neuron